Abstract
Immune checkpoint-blocking drugs such as ipilimumab, pembrolizumab, and nivolumab have demonstrated clinical efficacy as anticancer agents. Through modulation of immunoregulatory molecules, these novel therapeutics can produce durable cancer remissions in a variety of tumor types. As these medications are administered to an increasing number of patients, clinicians must be able to recognize and treat the associated immune-related side effects. This review summarizes the unique mechanisms of toxicity associated with immune checkpoint-blocking drugs, appropriate steps in patient evaluation, and strategies for mitigating risk and optimizing patient outcomes. Although the management of each patient receiving immune checkpoint-blockade therapy must be individualized, a conceptual framework upon which to base a multidisciplinary approach to best practices will help oncology practitioners deliver safe and effective care.
Original language | English (US) |
---|---|
Pages (from-to) | 30-38 |
Number of pages | 9 |
Journal | Oncology (Williston Park, N.Y.) |
Volume | 28 |
State | Published - Nov 1 2014 |
ASJC Scopus subject areas
- Oncology
- Cancer Research